About Proteostasis
Proteostasis is a company based in Boston (United States) founded in 2006. Proteostasis has raised $167.62 million across 6 funding rounds from investors including The Michael J. Fox Foundation, Eight Roads Ventures and Rock Springs Capital. The company has 11 employees. Proteostasis operates in a competitive market with competitors including Metabolon, Maze Therapeutics, Alector, Seer and Tango Therapeutics, among others.
- Headquarter Boston, United States
- Employees 11
- Stage Public
- SectorsHealthcare
- Website proteostasis.com
- Social LinkedIn X
- Legal Name Kineta, Inc./De
- Annual Revenue$5 M (USD)76as on Dec 31, 2019
- Net Profit-$59.13 M (USD)4as on Dec 31, 2019
- EBITDA-$61.15 M (USD)3as on Dec 31, 2019
- Total Equity Funding$167.62M (USD)
in 6 rounds
- Latest Funding Round$46M (USD), Post-IPO
Dec 2017
- InvestorsThe Michael J. Fox Foundation
& 8 more
- Employee Count11
Funding Insights of Proteostasis
Proteostasis has successfully raised a total of $167.62M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $46 million completed in December 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $167.62M
- Total Rounds 6
- Last Round Post-IPO β $46M
- First Round $45M
(Aug 2008)
- Investors Count 9
All 6 funding rounds of Proteostasis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2017 | $46M | Post-IPO | β | β | β |
| Sep 2015 | $37M | Series B | β | Cormorant Asset Management | |
| Jul 2014 | $15M | Series A | β | β | β |
| Jun 2013 | – | Grant | β | β | |
| Jun 2011 | $70.62M | Series A | β | β | |
| Aug 2008 | $45M | Series A | β | Healthcare Ventures |
9 investors in total: 9 institutional.
Investors in Proteostasis
Proteostasis has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include The Michael J. Fox Foundation, Eight Roads Ventures and Rock Springs Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage and late-stage biotech and finance companies are funded. | – | rockspringscapital.com | Baltimore, United States | |
Venture capital investments are offered to startups by NEA. | – | nea.com | Menlo Park, United States | |
- | – | hcven.com | - | |
Investments are made in innovative life science companies globally. | – | nvfund.com | Basel, Switzerland | |
Venture capital investment and global platform support for startups. | 2008 | eightroads.com | London, United Kingdom | |
Life-Sciences focused Early stage Corporate VC Firm investing in the US | – | sanofiventures.com | Paris, France | |
Healthcare startups are funded by this venture capital firm. | – | cormorantassetmanagement.tcc.mode | Ponte Vedra, United States | |
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | – | fprimecapital.com | - | |
Research for Parkinson's disease is funded by the foundation. | 2000 | michaeljfox.org | New York, United States |
Investor details for Proteostasis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Proteostasis
10 people are tracked at Proteostasis (3 in leadership, 6 in board & advisors, 1 in team); the tracked headcount is 11.
| Name | Role | Group |
|---|---|---|
Yulia Ovechkina | Associate Director, Immuno-oncology | Leadership |
Kurt Lustig | Director, Translational Development | Leadership |
Charles Magness | Co-founder | Leadership |
Michael A. Curran | Advisor | Board & advisors |
Myriam Chalabi | Advisor | Board & advisors |
Evan Y. Yu | Advisor | Board & advisors |
Marion R. Foote | Director | Board & advisors |
Lisa Coussens | Advisor | Board & advisors |
Patricia LoRusso | Advisor | Board & advisors |
Thu le | Controller | Team |
Complete people profiles for Proteostasis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Proteostasis
4 dated milestones of Proteostasis across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Proteostasis is founded.
- Funding First funding round of $45.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $46.0M.
Competitors of Proteostasis
Proteostasis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Metabolon, Maze Therapeutics, Alector, Seer and Tango Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| metabolon.com | 2000 | Morrisville, United States | $165.87M | 189 | Solutions for biomarker discovery and diagnostic testing are provided. | |
| mazetx.com | 2018 | Redwood, United States | $496M | 111 | Genetic biomarkers are developed for neurological, metabolic, and renal diseases. | |
| alector.com | 2013 | San Francisco, United States | $214.78M | 211 | Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | |
| seer.bio | 2017 | San Francisco, United States | $127.5M | 89 | Proteomics platform developed for early cancer and neurological disease detection. | |
| tangotx.com | 2017 | Cambridge, United States | $165M | 140 | Novel cancer drugs are developed using synthetic lethality screening. | |
| neophore.com | 2017 | Cambridge, United Kingdom | $44.56M | 10 | NeoPhore is focused on cancer neoantigen evolution therapies. | |
| scailyte.com | 2017 | Lucerne, Switzerland | $20.26M | – | Single-cell data is analyzed via AI for biomarker discovery. | |
| lexpharma.com | 1995 | United States | $165M | 135 | Small molecule drugs for various therapeutic areas are developed. | |
| denovobiopharma.com | 2013 | San Diego, United States | $171.82M | 42 | Genomic biomarker discovery platform is developed for drug personalization. | |
| hifibio.com | 2013 | Paris, France | $179.5M | – | Antibody-based drugs are discovered using a specialized technology platform. |
Detailed competitors of Proteostasis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Proteostasis
Websites that share an audience with Proteostasis (proteostasis.com).
Websites whose visitors overlap most with Proteostasis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| kempharm.com | 100% | 2.9K | #4,695,990 | View details | |
| ignyta.com | 90% | – | – | View details |
Latest news on Proteostasis
Complete news archive for Proteostasis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Proteostasis
10 companies that operate in the same segment as Proteostasis (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Proteostasis
Proteostasis was founded in 2006 and raised its 1st funding round 2 years after it was founded.
Proteostasis is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Proteostasis is a funded company, having raised a total of $167.62M across 6 funding rounds to date. The company's 1st funding round was a Series A of $45M, raised on Aug 2008.
Proteostasis has 11 employees.
Annual revenue of Proteostasis is $5M as on Dec 31, 2019.
Proteostasis Therapeutics is developing novel therapeutics for neurological disease. The company has developed a discovery platform that combines genomics, proteomics, and functional assays with medicinal chemistry and systems biology. Its drug pipeline includes modulator of CFTR (cystic fibrosis transmembrane conductance regulator) for the treatment of cystic fibrosis; Usp14 inhibitors to enhance clearance of aggregation-prone proteins such as Ξ±-synuclein in Parkinsons disease and tau in Alzheimers; modulators of the Unfolded Protein Response (UPR) to improve the stress response.
Proteostasis's top competitors include Alector, Lexicon Pharmaceuticals and Maze Therapeutics.
Proteostasis has 9 investors. Key investors include The Michael J. Fox Foundation, Eight Roads Ventures, Rock Springs Capital, NEA, and Healthcare Ventures.
Proteostasis operates through Kineta, Inc./De.